Palazestrant, a novel oral Complete Estrogen Receptor Antagonist (CERAN) and Selective Estrogen Receptor Degrader (SERD), in patients with ER+/HER2− advanced or metastatic breast cancer: phase 1/2 study results

Abstract Background Endocrine resistance is a major challenge in treating patients with ER+ /HER2− metastatic breast cancer (MBC) necessitating a switch from endocrine therapy to more toxic therapies. Mutations in ESR1 constitute a key mechanism of resistance to endocrine therapy in ER+ /HER2− BC. T...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Erika P. Hamilton, Manish R. Patel, Virginia F. Borges, Jane L. Meisel, Meena Okera, Carlos A. Alemany, Timothy J. Pluard, Robert Wesolowski, Dhanusha Sabanathan, Kathy D. Miller, Alison K. Conlin, Nicole McCarthy, Morena Shaw, Margaret Tonda, Mark Shilkrut, Nancy U. Lin
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2025-07-01
Serie:	Breast Cancer Research
Soggetti:	Complete estrogen receptor antagonist Selective estrogen receptor degrader Estrogen receptor-positive human epidermal growth factor receptor 2-negative metastatic breast cancer Endocrine therapy Palazestrant Estrogen receptor mutation
Accesso online:	https://doi.org/10.1186/s13058-025-02049-y
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!